Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
132 hedge funds and large institutions have $241M invested in Esperion Therapeutics in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 43 increasing their positions, 30 reducing their positions, and 28 closing their positions.
501% more call options, than puts
Call options by funds: $7.04M | Put options by funds: $1.17M
43% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 30
4% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 28
1% less funds holding
Funds holding: 133 → 132 (-1)
10% less capital invested
Capital invested by funds: $268M → $241M (-$26.8M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
101.72% less ownership
Funds ownership: 184.38% → 82.66% (-102%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$7.55M |
| 2 |
BlackRock
New York
|
+$6.53M |
| 3 |
Millennium Management
New York
|
+$3.92M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.13M |
| 5 |
JP Morgan Chase
New York
|
+$2.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$25M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$7.3M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$4.03M |
| 4 |
HF
HRT Financial
New York
|
-$1.18M |
| 5 |
D.E. Shaw & Co
New York
|
-$1.06M |
ESPR Hedge Fund Activity: Q1 2022 in Review
132 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q1 2022, worth a combined $241M — down 10% from $268M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ESPR positions and 28 closed out — a net gain of 1 holder — while 43 added to existing stakes and 30 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $7.55M. The largest seller was Deerfield Management, exiting entirely with an estimated $25M sold.
- 132 institutional investors held Esperion Therapeutics (ESPR) as of Q1 2022, down from 133 in Q4 2021.
- Funds reported $241M of Esperion Therapeutics stock for Q1 2022, down 10% quarter-over-quarter.
- 29 funds opened new Esperion Therapeutics positions in Q1 2022 and 28 closed out, a net change of +1 holder.
- The largest Esperion Therapeutics buyer in Q1 2022 was Wasatch Advisors, an estimated $7.55M added.
- The largest Esperion Therapeutics seller in Q1 2022 was Deerfield Management, an estimated $25M sold.
Based on aggregated 13F filings for Q1 2022.